Loading...
ZimVie Q1 2025 Earnings Report
ZimVie reported a decrease in net sales and a significant improvement in net loss for the first quarter of 2025.
Key Takeaways
ZimVie Inc. reported first quarter 2025 financial results with net sales of $112.0 million, a 5.2% decrease from the prior year. The company significantly improved its net loss, reducing it to $(2.6) million from $(11.5) million in the first quarter of 2024. Adjusted EBITDA also saw a substantial increase.
Net Sales from Continuing Operations were $112.0 million, a decrease of 5.2% reported and 4.1% in constant currency compared to Q1 2024.
Net Loss from Continuing Operations improved significantly to $(2.6) million from $(11.5) million in Q1 2024, with the net loss margin improving by 740 basis points.
Adjusted EBITDA from Continuing Operations increased to $17.6 million, or 15.7% of net sales, up $5.1 million or 520 basis points from Q1 2024.
Adjusted diluted EPS from Continuing Operations was $0.27, compared to GAAP diluted EPS of $(0.09).
ZimVie
ZimVie
ZimVie Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
ZimVie provided financial guidance for the full year ending December 31, 2025, projecting net sales between $445 million and $460 million, adjusted EBITDA between $65 million and $70 million, and adjusted EPS between $0.80 and $0.95.
Positive Outlook
- Projected Adjusted EBITDA of $65M to $70M indicates expected profitability.
- Projected Adjusted EPS of $0.80 to $0.95 suggests positive earnings per share.
- Management is focused on execution and operational diligence.
- Intention to drive operational efficiency and profitability improvements.
- Striving towards a return to top-line growth.
Challenges Ahead
- Net Sales guidance of $445M to $460M is lower than previous year's reported sales, indicating continued revenue decline.
- Forward-looking non-GAAP financial measures are not quantitatively reconciled to GAAP, implying potential material differences.
- The company acknowledges risks such as dependence on new product development and pricing pressures.
- Challenges related to changes in governmental laws and regulations are a concern.
- Impacts from healthcare reform measures and reductions in reimbursement levels could negatively affect financial performance.